N/A N=86 A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients
Vital Sign Evaluation
Primary: Pulse Rate Accuracy — 67 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=235 The Support, Educate, Empower (SEE) Program
Glaucoma
Primary: Mean Percent Electronically Monitored Medication Adherence Over Six Months — 77.6; 58.0 percent adherence — p=<0.001
Phase 3 N=554 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.9; -20.7; -19.7 score on a scale — p=0.514
N/A N=71 Enhancing Sexual Safety: Couples' Communication and HIV Testing Among YMSM
HIV/AIDS · HIV Infections
Primary: HIV Transmission Risk Behavior — 9; 11; 0; 4 Participants — p=0.20
N/A N=550 Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
Prostate Adenocarcinoma
Primary: Number of Patients Adhering to Cardiovascular Follow-up Recommendations in the Second Year After Radiation Treatment — 160; 157 Participants — p=0.9238
N/A N=56 High Flow vs Conventional Oxygen in Head and Neck Surgery
Pulmonary Disease
Primary: Proportion of Patients With Post-operative Pulmonary Complication — 2; 11 Participants
Phase 2 N=36 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Carcinoid Syndrome · Carcinoid · Carcinoid Tumor
Primary: Safety - Incidence of Treatment-emergent Adverse Events (TEAEs) — 16; 15; 10; 9 participants
Phase 2 N=496 A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
Early-stage Parkinson's Disease
Primary: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-III Sum Score at Day 0 — 34.0; 33.9; 30.6 score on a scale
N/A N=35 Performance of DAILIES TOTAL1 Daily Disposable Contact Lenses in Habitual Soft Lens Wearers Who Report Substantial Digital Device Use
Myopia
Primary: Subjective Rating of Comfort After 8 Hours or More of Digital Device Use — 96 score on a scale
N/A N=43 Organization-level Youth Engagement Approach for Substance Misuse Prevention
Drug Use · Substance Use · Opioid Use
Primary: Staff Surveys--Youth Engagement (YE) Prevention Programming Value — 4 score on a scale
N/A N=1,155 Harambee: Integrated Community-based HIV/NCD Care & Microfinance Groups in Kenya
HIV/AIDS · Noncommunicable Diseases · Hypertension
Primary: HIV-1 RNA Viral Load Suppression at 18-months — 326; 365; 275 Participants — p=0.23
Phase 3 N=166 Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo) — -0.55; 0.12 A1C Percentage
N/A N=21 Steps for Epilepsy
Epilepsy
Primary: Proportion of Participants Who Achieve Their Assigned Step Goal - Adherence — 0.267 Proportion
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
N/A N=40 Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Tachycardia Syndrome · Autonomic Dysfunction · Postural Orthostatic Tachycardia Syndrome
Primary: The Change in Composite Autonomic Symptom Score (COMPASS-31) — -5.40; -5.94 score on a scale